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What precautions should we use with
statins for women of childbearing age?
n Evidence summary
Hydroxymethyl glutaryl coenzyme A
(HMG CoA) reductase inhibitors, com-
monly called statins, have been on the
market since the late 1980s. Statins are pri-
marily used to treat hypercholesterolemia,
and in recent years have been shown to
reduce the risks of coronary events, stroke,
and cardiovascular mortality.1
Use of statins is contraindicated dur-
ing pregnancy based on pre-marketing
animal studies showing developmental
toxicities in animal fetuses; consequently
they are pregnancy category X.2 To date,
no controlled studies demonstrate terato-
genic effects in humans; however, numer-
ous case reports have documented con-
genital anomalies, including vertebral,
anal, cardiac, tracheal, esophageal, renal,
and limb deficiency (VACTERL associa-
tion), intrauterine growth retardation
(IUGR), and demise in fetuses exposed
during pregnancy, especially in the first
trimester. It is thought that adverse
events are under-reported and likely
biased toward severe outcomes, thereby
limiting actual reported exposures.
Despite this limitation, the likelihood of
observing specific anomalies has been
predicted based upon prescription data
and birth rates. The overall birth preva-
lence of any isolated lower-limb defect or
VACTERL anomaly is estimated as
1:100,000 and ranges from 1:50,000 for
simvastatin (Zocor) to 1:500,000 for
lovastatin (Mevacor).3 These congenital
Statins are contraindicated for women who are
pregnant or breastfeeding. Data evaluating statin
use for women of childbearing age is limited; how-
ever, they may be used cautiously with adequate
contraception. Pravastatin may be preferred based
on its low tissue-penetration properties.
Cholesterol-lowering with simvastatin 40 mg/d did
not disrupt menstrual cycles or effect luteal phase
duration (strength of recommendation: C).
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C L I N I C A L C O M M E N T A R Y
Use statins only as a last resort 
for women of childbearing age
I try to follow the USPSTF recommendations and
not screen women aged <45 years without coro-
nary artery disease risk factors for hyperlipidemia.
When a woman of any age needs treatment, my
first-line therapy is lifestyle modification. Given the
risks of statin drugs to the developing fetus,
women with childbearing potential should  give
fully informed consent and be offered reliable 
contraception before stating statin therapy. 
Before reading this review, I had not been
aware of the serious effects of statin medications
on the developing fetus. In conversations with 
my colleagues, I found that the adverse effects 
of statins during pregnancy are not readily
known. Such information needs to be more 
widely disseminated.
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anomaly frequencies do not exceed gen-
eral population rates.
One study suggests that short-term use
of simvastatin does not affect menstrua-
tion or ovulation of premenopausal
women. This double-blind, randomized,
placebo-controlled trial enrolled 86 nor-
mally cycling women. Mean age of women
completing the study was 35. Simvastatin
40 mg/d was studied for cholesterol effects
and female reproductive effects. Urinary
luteinizing hormone (LH) and pregnanedi-
ol glucuronide (PDG), a progesterone
metabolite, were assessed to determine if
treatment with simvastatin adversely
affects luteal function. Simvastatin lowered
low-density lipoprotein (LDL) cholesterol
by 34.3% (P<.001). Normal luteal phase
duration and peak were confirmed by uri-
nary PDG and LH levels. This study
demonstrated that treatment with simvas-
tatin for 4 months had no significant clini-
cal changes on reproductive gonadal func-
tion compared with placebo.4
Although ovulation may not be
affected by simvastatin, do statins provide
a reward worth the risk of other adverse
effects? A recent meta-analysis evaluated
the benefits of lipid-lowering medication
in trials of at least 1 year duration that
included women. Total and coronary
heart disease (CHD) mortality, nonfatal
myocardial infarction, revascularization,
and total CHD events were assessed
among women with and without cardio-
vascular disease (CVD). Ten trials includ-
ed statins. Of the 5 studies that reported
age, the average was 61 years. For women
without CVD, lipid-lowering treatment
was not shown to affect total or CHD
mortality. For women with known CVD,
hyperlipidemia treatment did not affect
total mortality, but was shown effective in
reducing CHD events, CHD mortality,
nonfatal myocardial infarction, and
revascularization; the relative risk of
CHD events for statin users was 0.80
(95% confidence interval [CI],
0.71–0.91). The number of women need-
ed to treat (NNT) to prevent an initial
CHD event was 140. For secondary pre-
vention, the NNT to prevent 1 CHD
event was 26. Since women of child-bear-
ing potential have lower probability of
CHD events compared to the older
women studied in this meta-analysis, the
expected benefit for younger women is
likely to be substantially lower.5
Consider initial pregnancy tests and
inform all women of childbearing age of
the possibility of fetal injury before starting
statin therapy.2 Highly lipophilic statins—
such as simvastatin, atorvastatin (Lipitor),
and lovastatin—achieve embryoplacental
concentrations similar to those of maternal
plasma. For this reason, if statin therapy is
needed, these agents should be avoided.
Pravastatin (Pravachol) is the most
hydrophilic statin and has no reports of
abnormal pregnancy outcomes, even in
animal research.3
Recommendations from others
The National Cholesterol Education
Program Expert Panel and the American
Heart Association make no specific 
recommendations regarding precautions
with statin use for women of child-
bearing age who require treatment for
hypercholesterolemia or coronary heart
disease.6,7 The American College of
Obstetrics and Gynecologists makes no
distinction regarding recommendations
for pharmacological treatment of hyper-
lipidemia for women aged 20 to 45
years.8
The US Preventive Services Task
Force makes no recommendations on
treatment with statins; they only address
screening for hypercholesterolemia.9 The
Food and Drug Administration has given
statin agents a pregnancy category of X
(risks involved in use of the drug by preg-
nant women clearly outweigh potential
benefits).
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